Suppr超能文献

使用非放射性标记激动剂二丙基-5,6-ADTN进行的体内多巴胺受体结合研究。

In vivo dopamine receptor binding studies with a non-radioactively labeled agonist, dipropyl-5,6-ADTN.

作者信息

Feenstra M G, Rollema H, Mulder T B, Westerink B H, Horn A S

出版信息

Life Sci. 1983 Mar 21;32(12):1313-23. doi: 10.1016/0024-3205(83)90805-6.

Abstract

Evidence is presented that a low dose of peripherally administered N,N-dipropylamino-5,6-dihydroxytetralin (DiPr-5,6-ADTN) specifically labels dopamine (DA) receptors in rat brain. Concentrations of this potent DA receptor agonist were determined by a highly selective method using reversed phase liquid chromatography and amperometric detection. The binding characteristics satisfy all criteria regarding saturability, stereospecificity, regional distribution and relation with pharmacological effects that are associated with DA receptor interactions. A rough estimation of the density of binding sites in the striatum resulted in values of 60-70 pmol/g. Lesioning the nigrostriatal pathway does not significantly alter the amount of ligand bound, nor do pretreatments with serotonergic, alpha-adrenergic or beta-adrenergic antagonists. DiPr-5,6-ADTN has thus been shown to be a useful ligand for labeling central DA receptors and a powerful tool in the study of DA-ergic mechanisms.

摘要

有证据表明,低剂量外周给予的N,N-二丙基氨基-5,6-二羟基四氢萘(DiPr-5,6-ADTN)能特异性标记大鼠脑中的多巴胺(DA)受体。采用反相液相色谱和安培检测的高选择性方法测定了这种强效DA受体激动剂的浓度。其结合特性满足与DA受体相互作用相关的关于饱和性、立体特异性、区域分布以及与药理作用关系的所有标准。对纹状体中结合位点密度的粗略估计得出的值为60 - 70 pmol/g。损毁黑质纹状体通路不会显著改变结合的配体量,用血清素能、α-肾上腺素能或β-肾上腺素能拮抗剂预处理也不会改变。因此,DiPr-5,6-ADTN已被证明是用于标记中枢DA受体的有用配体以及研究多巴胺能机制的有力工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验